SciCombinator

Discover the most talked about and latest scientific content & concepts.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

OPEN The New England journal of medicine | 9 Jun 2015

JB Green, MA Bethel, PW Armstrong, JB Buse, SS Engel, J Garg, R Josse, KD Kaufman, J Koglin, S Korn, JM Lachin, DK McGuire, MJ Pencina, E Standl, PP Stein, S Suryawanshi, F Van de Werf, ED Peterson and RR Holman
Abstract
Background Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. Methods In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Results During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32). Conclusions Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205 .).
Tweets*
114
Facebook likes*
22
Reddit*
0
News coverage*
6
Blogs*
1
SC clicks
0
Concepts
Cardiovascular diseases, Diabetes mellitus type 2, Cardiovascular disease, Hypertension, Atherosclerosis, Obesity, Diabetes mellitus, Myocardial infarction
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com